Clinical meaning of BRAF mutation in Korean patients with advanced colorectal cancer

World Journal of Gastroenterology

Volumn 20, Issue 15, 2014, Pages 4370-4376

  Kim, Bun ^a   Park, Soo Jung ^a   Cheon, Jae Hee ^a   Kim, Tae Il ^a   Kim, Won Ho ^a   Hong, Sung Pil ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

BRAF; Chemotherapy response; Colorectal cancer; Molecular features; Prognosis

Indexed keywords

B RAF KINASE; K RAS PROTEIN; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; COLON MUCOSA; COLORECTAL CANCER; DNA SEQUENCE; FEMALE; FOLLOW UP; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; OVERALL SURVIVAL; PHENOTYPE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; V RAF MURINE SARCOMA VIRAL ONCOGENE HOMOLOG B1 GENE; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; NUCLEOTIDE SEQUENCE; SOUTH KOREA; TREATMENT OUTCOME;

AGED; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; REPUBLIC OF KOREA; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84898901842     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i15.4370     Document Type: Article

References (30)

1. Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS. Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat 2013; 45: 1-14 [PMID: 23613665 DOI: 10.4143/crt.2013.45.1.1]
2. Zlobec I, Lugli A. Prognostic and predictive factors in colorectal cancer. J Clin Pathol 2008; 61: 561-569 [PMID: 18326017 DOI: 10.1136/jcp.2007.054858]
3. Jass JR. Molecular heterogeneity of colorectal cancer: Implications for cancer control. Surg Oncol 2007; 16 Suppl 1: S7-S9 [PMID: 18023574 DOI: 10.1016/j.suronc.2007.10.039]
4. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247-257 [PMID: 12867608 DOI: 10.1056/NEJMoa022289]
5. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23: 609-618 [PMID: 15659508 DOI: 10.1200/ jco.2005.01.086]
6. French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, Shepherd L, Windschitl HE, Thibodeau SN. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res 2008; 14: 3408-3415 [PMID: 18519771 DOI: 10.1158/1078-0432. ccr-07-1489]
7. Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R, Qian ZR, Morikawa T, Shen J, Meyerhardt JA, Fuchs CS, Ogino S. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 2013; 105: 1151-1156 [PMID: 23878352 DOI: 10.1093/ jnci/djt173]
8. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27: 5924-5930 [PMID: 19884556 DOI: 10.1200/jco.2008.21.6796]
9. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773: 1263-1284 [PMID: 17126425 DOI: 10.1016/j.bbamcr.2006.10.001]
10. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009; 101: 1308-1324 [PMID: 19738166 DOI: 10.1093/jnci/djp280]
11. Samowitz WS, Albertsen H, Herrick J, Levin TR, Sweeney C, Murtaugh MA, Wolff RK, Slattery ML. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 2005; 129: 837-845 [PMID: 16143123 DOI: 10.1053/j.gastro.2005.06.020]
12. Saridaki Z, Papadatos-Pastos D, Tzardi M, Mavroudis D, Bairaktari E, Arvanity H, Stathopoulos E, Georgoulias V, Souglakos J. BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome. Br J Cancer 2010; 102: 1762-1768 [PMID: 20485284 DOI: 10.1038/sj.bjc.6605694]
13. Nosho K, Irahara N, Shima K, Kure S, Kirkner GJ, Schernhammer ES, Hazra A, Hunter DJ, Quackenbush J, Spiegelman D, Giovannucci EL, Fuchs CS, Ogino S. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One 2008; 3: e3698 [PMID: 19002263 DOI: 10.1371/journal. pone.0003698]
14. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765 [PMID: 18946061 DOI: 10.1056/NEJMoa0804385]
15. Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009; 361: 98-99 [PMID: 19571295 DOI: 10.1056/NEJMc0904160]
16. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-474 [PMID: 20008640 DOI: 10.1200/jco.2009.23.3452]
17. Yokota T, Ura T, Shibata N, Takahari D, Shitara K, Nomura M, Kondo C, Mizota A, Utsunomiya S, Muro K, Yatabe Y. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 2011; 104: 856-862 [PMID: 21285991 DOI: 10.1038/bjc.2011.19]
18. Bengala C, Bettelli S, Bertolini F, Sartori G, Fontana A, Malavasi N, Depenni R, Zironi S, Del Giovane C, Luppi G, Conte PF. Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. Br J Cancer 2010; 103: 1019-1024 [PMID: 20842128 DOI: 10.1038/ sj.bjc.6605853]
19. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047 [PMID: 10744089]
20. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Lévi F. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-147 [PMID: 10623704]
21. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz JF, Sinicrope F, Gallinger S. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28: 3219-3226 [PMID: 20498393 DOI: 10.1200/jco.2009.27.1825]
22. Vaughn CP, Zobell SD, Furtado LV, Baker CL, Samowitz WS. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 2011; 50: 307-312 [PMID: 21305640 DOI: 10.1002/gcc.20854]
23. Kang GH. Four molecular subtypes of colorectal cancer and their precursor lesions. Arch Pathol Lab Med 2011; 135: 698-703 [PMID: 21631262 DOI: 10.1043/2010-0523-ra.1]
24. Rhee YY, Kim MJ, Bae JM, Koh JM, Cho NY, Juhnn YS, Kim D, Kang GH. Clinical outcomes of patients with microsatelliteunstable colorectal carcinomas depend on L1 methylation level. Ann Surg Oncol 2012; 19: 3441-3448 [PMID: 22618722 DOI: 10.1245/s10434-012-2410-7]
25. Slattery ML, Curtin K, Wolff RK, Boucher KM, Sweeney C, Edwards S, Caan BJ, Samowitz W. A comparison of colon and rectal somatic DNA alterations. Dis Colon Rectum 2009; 52: 1304-1311 [PMID: 19571709 DOI: 10.1007/DCR.0b013e3181a0e5df]
26. Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, Liao X, Waldron L, Hoshida Y, Huttenhower C, Chan AT, Giovannucci E, Fuchs C, Ogino S. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012; 61: 847-854 [PMID: 22427238 DOI: 10.1136/gutjnl-2011-300865]
27. Sahin IH, Kazmi SM, Yorio JT, Bhadkamkar NA, Kee BK, Garrett CR. Rare Though Not Mutually Exclusive: A Report of Three Cases of Concomitant KRAS and BRAF Mutation and a Review of the Literature. J Cancer 2013; 4: 320-322 [PMID: 23569465 DOI: 10.7150/jca.3619]
28. Brim H, Mokarram P, Naghibalhossaini F, Saberi-Firoozi M, Al-Mandhari M, Al-Mawaly K, Al-Mjeni R, Al-Sayegh A, Raeburn S, Lee E, Giardiello F, Smoot DT, Vilkin A, Boland CR, Goel A, Hafezi M, Nouraie M, Ashktorab H. Impact of BRAF, MLH1 on the incidence of microsatellite instability high colorectal cancer in populations based study. Mol Cancer 2008; 7: 68 [PMID: 18718023 DOI: 10.1186/1476-4598-7-68]
29. Hong SP, Min BS, Kim TI, Cheon JH, Kim NK, Kim H, Kim WH. The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer. Eur J Cancer 2012; 48: 1235-1243 [PMID: 22071131 DOI: 10.1016/j.ejca.2011.10.005]
30. Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, Wolff RK, Slattery ML. Poor survival associated with the BRAF V600E mutation in microsatellitestable colon cancers. Cancer Res 2005; 65: 6063-6069 [PMID: 16024606 DOI: 10.1158/0008-5472.can-05-0404]